Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

729 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential diagnosis of suspected multiple sclerosis: global health considerations.
Correale J, Solomon AJ, Cohen JA, Banwell BL, Gracia F, Gyang TV, de Bedoya FHD, Harnegie MP, Hemmer B, Jacob A, Kim HJ, Marrie RA, Mateen FJ, Newsome SD, Pandit L, Prayoonwiwat N, Sahraian MA, Sato DK, Saylor D, Shi FD, Siva A, Tan K, Viswanathan S, Wattjes MP, Weinshenker B, Yamout B, Fujihara K. Correale J, et al. Among authors: cohen ja. Lancet Neurol. 2024 Oct;23(10):1035-1049. doi: 10.1016/S1474-4422(24)00256-4. Lancet Neurol. 2024. PMID: 39304243 Review.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB. Johnson KP, et al. Among authors: cohen ja. Neurology. 1995 Jul;45(7):1268-76. doi: 10.1212/wnl.45.7.1268. Neurology. 1995. PMID: 7617181 Clinical Trial.
Serum angiotensin-converting enzyme in multiple sclerosis.
Constantinescu CS, Goodman DB, Grossman RI, Mannon LJ, Cohen JA. Constantinescu CS, et al. Among authors: cohen ja. Arch Neurol. 1997 Aug;54(8):1012-5. doi: 10.1001/archneur.1997.00550200068012. Arch Neurol. 1997. PMID: 9267976
Management of multiple sclerosis.
Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Rudick RA, et al. Among authors: cohen ja. N Engl J Med. 1997 Nov 27;337(22):1604-11. doi: 10.1056/NEJM199711273372207. N Engl J Med. 1997. PMID: 9371858 Review. No abstract available.
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS. Johnson KP, et al. Among authors: cohen ja. Neurology. 1998 Mar;50(3):701-8. doi: 10.1212/wnl.50.3.701. Neurology. 1998. PMID: 9521260 Clinical Trial.
Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN; IMPACT Investigators. Cohen JA, et al. Neurology. 2002 Sep 10;59(5):679-87. doi: 10.1212/wnl.59.5.679. Neurology. 2002. PMID: 12221157 Clinical Trial.
729 results